EELS (Ethical, Economic, Legal & Social) Article
The Pharmacogenomics Journal (2006) 6, 154–157. doi:10.1038/sj.tpj.6500364; published online 17 January 2006
Pharmacogenomics and regulatory decision making: an international perspective
D L Mendrick1, C Brazell2, E A Mansfield3, R Pietrusko4, I Barilero5, J Hackett6, S Stürzebecher7 and D Jacobson-Kram8
- 1Toxicogenomics, Gene Logic Inc., Gaithersburg, MD, USA
- 2Genetics Research, GlaxoSmithKline, Middlesex, UK
- 3Regulatory Affairs, Affymetrix Inc., Santa Clara, CA, USA
- 4Worldwide Regulatory Affairs, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA
- 5Global Regulatory Policy and Intelligence, Johnson & Johnson Pharmaceutical Research and Development, High Wycombe, Bucks, UK
- 6Office of In Vitro Diagnostic Device Evaluation and Safety, CDRH, Rockville, MD, USA
- 7Corporate Preclinical Development, Schering AG, Berlin, Germany
- 8Office of New Drugs, CDER, Rockville, MD, USA
Correspondence: DL Mendrick, Toxicogenomics, Gene Logic Inc., 610 Professional Drive, Gaithersburg, MD 20879, USA. E-mail: dmendrick@genelogic.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective
Nature Reviews Drug Discovery Perspective (01 Sep 2004)
The US Food and Drug Administration perspective on cancer biomarker development
Nature Reviews Cancer Perspective (01 Jul 2006)
The Pharmacogenomics Journal Review
The Pharmacogenomics Journal Review
RESEARCH
Drug development: assessment of pharmacogenetic studies by Spanish research ethics committees
The Pharmacogenomics Journal Article Response
